[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Dyne Therapeutics Inc (DYN)

Dyne Therapeutics Inc (DYN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,850,013
  • Shares Outstanding, K 165,314
  • Annual Sales, $ 0 K
  • Annual Income, $ -446,210 K
  • EBIT $ -471 M
  • EBITDA $ -471 M
  • 60-Month Beta 1.09
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.69

Options Overview Details

View History
  • Implied Volatility 131.07% (+9.52%)
  • Historical Volatility 62.88%
  • IV Percentile 59%
  • IV Rank 32.38%
  • IV High 253.75% on 10/21/25
  • IV Low 72.33% on 08/18/25
  • Expected Move (DTE 15) 1.28 (7.26%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 42
  • Volume Avg (30-Day) 116
  • Put/Call OI Ratio 1.42
  • Today's Open Interest 5,055
  • Open Int (30-Day) 4,340
  • Expected Range 16.30 to 18.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.74
  • Number of Estimates 8
  • High Estimate $-0.68
  • Low Estimate $-0.84
  • Prior Year $-0.97
  • Growth Rate Est. (year over year) +23.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.87 +11.09%
on 05/19/26
19.61 -10.10%
on 05/29/26
+0.24 (+1.38%)
since 05/01/26
3-Month
14.41 +22.35%
on 03/04/26
21.43 -17.73%
on 04/15/26
+3.03 (+20.75%)
since 03/03/26
52-Week
8.06 +118.73%
on 07/07/25
25.00 -29.48%
on 10/28/25
+4.36 (+32.86%)
since 06/03/25

Most Recent Stories

More News
Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)

- Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 -  WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage...

DYN : 17.55 (+1.80%)
Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)

- Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion cohort of the DELIVER trial, treatment with z-rostudirsen resulted in a robust...

DYN : 17.55 (+1.80%)
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...

DYN : 17.55 (+1.80%)
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval

- 72-week trial will enroll approximately 90 participants; first site now open for enrollment - - Primary endpoint is rise from floor (RFF) velocity with multiple secondary endpoints to assess muscle...

DYN : 17.55 (+1.80%)
Dyne Therapeutics to Participate in Upcoming Investor Conferences

WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...

DYN : 17.55 (+1.80%)
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

- Positive pre-BLA meeting completed with FDA for z-rostudirsen in exon 51 DMD; on track for BLA submission in Q2 2026 and potential launch in Q1 2027 - - Positive cardiopulmonary results and long-term...

DYN : 17.55 (+1.80%)
Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCEâ„¢ Platform at 2026 ASGCT Annual Meeting

- Data underscore the differentiated capability of the clinically validated FORCE platform to cross the blood-brain barrier - WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics,...

DYN : 17.55 (+1.80%)
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...

DYN : 17.55 (+1.80%)
Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines

- Poster on previously shared positive results from DELIVER clinical trial in Duchenne muscular dystrophy (DMD) contextualizes observed clinical measures of functional improvement for managed care experts...

DYN : 17.55 (+1.80%)
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)

- HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1  - - 48-week trial will enroll approximately 150 individuals, and first sites are now open for...

DYN : 17.55 (+1.80%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Bearish.

See More Share

Business Summary

Dyne Therapeutics Inc. is a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases. The company's proprietary platform includes FORCE(TM). Dyne Therapeutics Inc. is based in WALTHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 19.69
2nd Resistance Point 19.09
1st Resistance Point 18.16
Last Price 17.55
1st Support Level 16.64
2nd Support Level 16.04
3rd Support Level 15.11

See More

52-Week High 25.00
Fibonacci 61.8% 18.53
Last Price 17.55
Fibonacci 50% 16.53
Fibonacci 38.2% 14.53
52-Week Low 8.06

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.